SNCE Science 37 Holdings Inc

Today, Science 37, a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global Company of the Year Award. Recognizing the market participant that exemplifies visionary innovation, market-leading performance, and unmatched customer care, the award solidifies Science 37’s growing influence in the clinical trial industry as it increasingly turns to decentralization to help overcome recruitment, enrollment, and retention challenges.

The internationally respected business consulting firm selected Science 37 after applying a rigorous analytical process that considered multiple nominees. A detailed evaluation of Best Practices criteria across two dimensions resulted in Science 37 earning the consultancy’s top honor in the decentralized clinical trials space. “Frost & Sullivan applauds Science 37 for its exemplary implementation of best practices driven by an excellent development strategy,” commented Valentina Barcia, Best Practices Research Analyst at Frost & Sullivan.

“We are deeply honored to receive the Frost & Sullivan’s Best Practices Award,” said David Coman, Chief Executive Officer at Science 37. “This recognition as the leader in decentralized clinical trials underscores the vision, dedication, and hard work of our entire team. We remain committed to transforming the clinical trial process to better serve patients and sponsors alike.”

To learn more about Science 37 and its award-winning approach, read the full Frost & Sullivan report.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. For more information, visit www.frost.com

About Science 37Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37PR@science37.com